Invivyd, Inc.
Close on Oct 19, 2026
- Market cap
- $195.47M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $14.30M | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $13.70M | $-0.13 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $17.20M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $13.10M | $-0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $11.80M | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $-0.14 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 3, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Invivyd filed with the SEC
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Executive or director change · Other events · EX-99.1 to Form 8-K
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis presentation contains forward-looking statements within the meaning of the U.S.
Results of operations · Other events · EX-99.2 to Form 8-K
REVOLUTION Program & Measles April 9, 2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the
Other events · EX-99.2 to Form 8-K
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and
Results of operations · Other events · EX-99.1 to Form 8-K
2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1
Results of operations · Other events · EX-99.2 to Form 8-K
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Inc. All trademarks used in this presentation are the property of their respective owners. 1
Results of operations · Other events · EX-99.2 to Form 8-K
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Other events · EX-99.1 to Form 8-K
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
Other events · EX-99.1 to Form 8-K
Invivyd Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.2 to Form 8-K
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
2025 © 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1
Results of operations · Other events · EX-99.2 to Form 8-K
Life can only be understood backwards; but it must be lived forwards KIERKEGAARD Invivyd 1
Other events · EX-99.1 to Form 8-K
INVIVYD APPOINTS PAUL B. BOLNO, M.D. TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Invivyd Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.2 to Form 8-K
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
Material agreement · Other events · EX-99.3 to Form 8-K
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311
Results of operations · Other events · EX-99.2 to Form 8-K
Invivyd®, the Invivyd logo, Pemgarda® and the Ribbon logo are registered trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. 1
Results of operations · Other events · EX-99.3 to Form 8-K
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
May 15, 2025 © 2025 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Results of operations · Other events · EX-99.2 to Form 8-K
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
Other events · EX-99.1 to Form 8-K
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
Other events · EX-99.1 to Form 8-K
The COVID-19 treatment opportunity for pemivibart was not contemplated in existing financial guidance
Other events · EX-99.1 to Form 8-K
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
Results of operations · Other events · EX-99.1 to Form 8-K
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
Results of operations · Other events · EX-99.2 to Form 8-K